Frontier mental health research: psychedelics & drug studies

Key findings

• Only a very small number of clinical trials have tested ayahuasca for anxiety; one recent review counted one ayahuasca trial among nine psychedelic trials for anxiety disorders. ¹⁵⁰⁶⁸
• Across the broader psychedelic studies, researchers often saw reductions in anxiety symptoms after treatment, but many trials used different drugs or mixed methods, so results are not all about ayahuasca alone. ^{15068 15058}
• People who took psychedelics (including ayahuasca in some reports) commonly describe gaining personal insights, feeling changed in their sense of self, and feeling more connected to others—experiences they say helped reduce worry. ^{15092 15059 15063}
• Ayahuasca contains DMT, a naturally occurring compound that acts on serotonin brain systems (a chemical system that affects mood and perception). ^{15059 15050}
• Lab and animal studies show DMT can increase growth of neuron branches and synapses (this is called "neuroplasticity", meaning the brain’s wiring can change). These findings are in cells or animals, not yet proven in people. ^{15050 15091}
• A large review looking at many psychoplastogen drugs found no clear rise in a common blood marker (BDNF) after drug use, so blood biomarker evidence for brain change is unclear. ¹⁵¹²⁹
• Psychedelic treatments carry risks and need careful medical and therapeutic support. Some drugs in the field (for example ibogaine) have serious physical risks, and animal studies show effects can depend on dose and sex, which raises safety questions for humans. ^{15091 15085 15050}
• The current evidence is limited: many studies are small or early‑stage and often include mostly white participants. That means we do not yet know how long benefits last, who is most likely to benefit, or what the safest, most effective dose and setting are. ^{15068 15095 15087 15091}